Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19.
Sarah M LofgrenMelanie R NicolAnanta S BangdiwalaKatelyn A PastickElizabeth C OkaforCaleb P SkipperMatthew Flinn PullenNicole W EngenMahsa AbassiDarlisha A WilliamsAlanna A NasceneMargaret L AxelrodSylvian A LotherLauren J MacKenzieGlen DrobotNicole MartenMatthew Pellan ChengRyan ZarychanshiIlan S SchwartzMichael SilvermanZain ChaglaLauren E KellyEmily Gibson McDonaldTodd C LeeKatherine Huppler HullsiekDavid R BoulwareRadha RajasinghamPublished in: medRxiv : the preprint server for health sciences (2020)
Data from three outpatient COVID-19 trials demonstrated that gastrointestinal side effects were common but mild with the use of hydroxychloroquine, while serious side effects were rare. No deaths occurred related to hydroxychloroquine. Randomized clinical trials can safely investigate whether hydroxychloroquine is efficacious for COVID-19.